Chemo Update 6 5 24 The phase iii checkmate 9la study demonstrated durable overall survival (os) benefit with nivolumab plus ipilimumab with chemotherapy versus chemotherapy in patients with metastatic non small cell lung cancer (nsclc). here, we report final, 6 year efficacy and safety outcomes. He will still continue to take his chemo pills as planned. some good news from today, his cea numbers are still low and haven’t moved much since his last bloodwork 3 weeks ago!!.
Chemo News Chemo News Chemo Information Impower010 is the first study to report survival outcomes with a ≥5 year follow up and continued to show benefit with atezolizumab versus bsc after adjuvant chemotherapy in patients with resected stage ii iiia pd l1–selected nsclc. In a randomized trial including 381 such patients, relacorilant plus nab paclitaxel versus nab paclitaxel alone improved both progression free survival (6.5 versus 5.5 months) and overall survival (16 versus 11.5 months). Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event free survival in patients with resectable non–small cell lung cancer (nsclc) in a phase 3. In response to the ever changing practice of cancer care, in may 2024, the american society of clinical oncology (asco) and ons released updates to their administration safety standards to provide clarification and guidance for oncology healthcare professionals.
Chemotherapy Updates Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event free survival in patients with resectable non–small cell lung cancer (nsclc) in a phase 3. In response to the ever changing practice of cancer care, in may 2024, the american society of clinical oncology (asco) and ons released updates to their administration safety standards to provide clarification and guidance for oncology healthcare professionals. This is a phase iii, randomised, open label, 3 arm, multicentre, international study assessing the efficacy and safety of dato dxd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with pd l1 positive locally recurrent inoperable or metastatic tnbc. After a median follow up of 41.6 months, use of pembrolizumab chemotherapy continued to show improved clinical outcomes vs placebo chemotherapy regardless of pd l1 expression. This 5 year update supports the long term, durable os benefit and improved 5 year survivorship with nivolumab plus ipilimumab with chemotherapy over chemotherapy in patients with mnsclc, regardless of tumor pd l1 expression or histology. The clinically meaningful efs and os benefit of adding perioperative pembro to neoadjuvant chemo in pts with early stage nsclc is maintained over ⁓4 years of follow up, supporting this regimen as a standard of care treatment option for this population.
Comments are closed.